We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
101
Aurinia Pharmaceuticals
AUPH
$1.88B
$5.59M 0.18%
252,821
-145,099
-36% -$2.3M
QGEN icon
102
Qiagen
QGEN
$8.64B
$5.57M 0.18%
+101,713
New +$5.66M
ELV icon
103
Elevance Health
ELV
$82.1B
$5.46M 0.18%
14,644
-93,090
-86% -$35.4M
VECT
104
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$5.37M 0.17%
756,502
+611,502
+422% +$5.24M
TVTX icon
105
Travere Therapeutics
TVTX
$5.08B
$5.16M 0.17%
212,869
– –
KURA icon
106
Kura Oncology
KURA
$806M
$5.12M 0.16%
273,463
– –
DOC icon
107
Healthpeak Properties
DOC
$15.1B
$5.04M 0.16%
150,392
– –
ARNA
108
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.98M 0.16%
83,629
-112,756
-57% -$6.66M
ALGN icon
109
Align Technology
ALGN
$12.3B
$4.96M 0.16%
7,459
-2,466
-25% -$1.67M
TBPH icon
110
Theravance Biopharma
TBPH
$874M
$4.86M 0.16%
656,296
– –
RCM
111
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.45M 0.14%
202,351
– –
FATE icon
112
Fate Therapeutics
FATE
$296M
$4.31M 0.14%
72,727
– –
VRNA
113
DELISTED
Verona Pharma
VRNA
$4.12M 0.13%
751,905
– –
ZLAB icon
114
Zai Lab
ZLAB
$2.07B
$3.96M 0.13%
37,523
– –
MREO
115
Mereo BioPharma
MREO
$53.7M
$3.75M 0.12%
1,551,082
+506,292
+48% +$1.34M
RMD icon
116
ResMed
RMD
$31.1B
$3.74M 0.12%
14,189
-123,618
-90% -$33.8M
AFMD
117
DELISTED
Affimed
AFMD
$3.62M 0.12%
58,604
-32,270
-36% -$2.12M
SRRK icon
118
Scholar Rock
SRRK
$5.57B
$3.59M 0.12%
108,833
– –
MEDP icon
119
Medpace
MEDP
$16B
$3.57M 0.12%
18,871
– –
VIR icon
120
Vir Biotechnology
VIR
$1.48B
$3.54M 0.11%
81,400
– –
STVN icon
121
Stevanato
STVN
$5.49B
$3.49M 0.11%
+137,872
New +$3.25M
FMTX
122
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$3.47M 0.11%
149,825
– –
TAK icon
123
Takeda Pharmaceutical
TAK
$54B
$3.44M 0.11%
210,146
– –
STE icon
124
Steris
STE
$22.6B
$3.4M 0.11%
16,669
-10,986
-40% -$2.35M
ARQT icon
125
Arcutis Biotherapeutics
ARQT
$3.27B
$3.15M 0.1%
131,633
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.